Free Trial

Insulet Q1 2023 Earnings Report

Insulet logo
$266.57 +10.01 (+3.90%)
(As of 12/20/2024 05:51 PM ET)

Insulet EPS Results

Actual EPS
$0.23
Consensus EPS
$0.09
Beat/Miss
Beat by +$0.14
One Year Ago EPS
$0.40

Insulet Revenue Results

Actual Revenue
$358.10 million
Expected Revenue
$330.21 million
Beat/Miss
Beat by +$27.89 million
YoY Revenue Growth
+21.20%

Insulet Announcement Details

Quarter
Q1 2023
Time
After Market Closes

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Insulet Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Insulet (NASDAQ:PODD) Hits New 1-Year High on Analyst Upgrade
See More Insulet Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Insulet? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Insulet and other key companies, straight to your email.

About Insulet

Insulet (NASDAQ:PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

View Insulet Profile

More Earnings Resources from MarketBeat

Upcoming Earnings